Autolus Therapeutics Ltd (AUTL) ADS Each Rep 1 Ord Shs
$0.055
(2.44%)
- Add to watchlist
- This stock can be held in a
$0.055
(2.44%)
$0.055
(2.44%)
Share news, reports & tips
-
Syncona's Autolus leukemia treatment meets trial endpoint
9 December 2022 07:21
(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.
Company announcements Announcements
No company announcements about Autolus Therapeutics Ltd ADS Each Rep 1 Ord Shs were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.